NEW YORK (GenomeWeb News) – Sangamo BioSciences and Sigma-Aldrich said today that Roche has licensed Sangamo’s zinc finger nuclease technology to develop cell lines and transgenic animals that have targeted modifications in specific genes.
Zinc finger nucleases are engineered forms of zinc finger DNA-binding proteins that can be used to help modify target genes in organisms. Sigma-Aldrich is the exclusive licensee of Sangamo’s ZFN technology for research reagents.
Under the agreement, Roche will receive a non-exclusive, worldwide research license to Sangamo’s ZFN technology in exchange for research maintenance fees and research event payments, and it will conduct research with both Sangamo and Sigma-Aldrich.
Roche also has an option to obtain an exclusive, worldwide license for the commercial use of ZFN-generated transgenic animals in the production of therapeutic and diagnostic products.
If it exercises this option, it will pay an additional license fee, as well as payments on clinical milestones and royalties from the sale of therapeutic and diagnostic products.